PRODUCT MONOGRAPH

**METHOTREXATE INJECTION USP**

25 mg/mL
Sterile
solution for injection

Antimetabolite and Antirheumatic

Sandoz Canada Inc.
145, Jules-Léger
Boucherville, Quebec
J4B 7K8

Date of Revision: September 21, 2016

Submission Control No: 196722
# Table of Contents

## PART I: HEALTH PROFESSIONAL INFORMATION
- SUMMARY PRODUCT INFORMATION .......................................................... 3
- INDICATIONS AND CLINICAL USE .......................................................... 3
- CONTRAINDICATIONS ............................................................................. 4
- WARNINGS AND PRECAUTIONS ............................................................ 5
- ADVERSE REACTIONS ............................................................................ 13
- DRUG INTERACTIONS ............................................................................ 15
- DOSAGE AND ADMINISTRATION ......................................................... 18
- OVERDOSAGE ...................................................................................... 24
- ACTION AND CLINICAL PHARMACOLOGY ......................................... 24
- STORAGE AND STABILITY ................................................................. 27
- SPECIAL HANDLING INSTRUCTIONS ................................................ 27
- DOSAGE FORMS, COMPOSITION AND PACKAGING ........................... 28

## PART II: SCIENTIFIC INFORMATION
- PHARMACEUTICAL INFORMATION ....................................................... 30
- DETAILED PHARMACOLOGY ................................................................. 31
- TOXICOLOGY ....................................................................................... 33
- REFERENCES ......................................................................................... 34

## PART III: CONSUMER INFORMATION .................................................... 39
PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>All Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>intramuscular, intravenous, intra-arterial</td>
<td>Solution for injection/25 mg/mL</td>
<td>Benzyl alcohol (preservative), hydrochloric acid, sodium chloride, sodium hydroxide and water for injection.</td>
</tr>
</tbody>
</table>

INDICATIONS AND CLINICAL USE

Two major fields of indication exist for Methotrexate Injection USP:

- Neoplastic diseases
- Disease Modifying Antirheumatic Drug (DMARD)

Neoplastic Diseases

- Choriocarcinoma: Methotrexate - as single chemotherapy or in combination with other drugs.
- Intermediate-, or high grade Non-Hodgkin's Lymphoma as part of ProMACE-CytaBOM, ProMACE-MOPP, and Magrath protocols.
- Breast Cancer: as part of CMF (cyclophosphamide-methotrexate-fluorouracil) therapy.
- Acute Lymphoblastic Leukemia (ALL) - as maintenance therapy.
- Head and Neck Cancer - in combination with other chemotherapies.
- Gastric Cancer – palliative combination chemotherapy.
- Metastasis of unknown primary - as palliative combination chemotherapy.
- Bladder Cancer (advanced) - as part of M-VAC regimen.
- Burkitt's lymphoma.
- Advanced stages of childhood lymphoma (III and IV, St. Jude's Childrens' Research Hospital Staging System).
- Advanced cases of mycosis fungoids (cutaneous T-cell lymphoma).

Disease Modifying Antirheumatic Drug (DMARD)

The use of methotrexate as a DMARD in the following diseases where standard therapeutic interventions fail:
• Severe disabling psoriasis/psoriatic arthritis
• Severe disabling rheumatoid arthritis (RA)
• Severe disabling seronegative arthritides

In the treatment of psoriasis, methotrexate should be restricted to severe recalcitrant, disabling
psoriasis, which is not adequately responsive to other forms of therapy, but only when the
diagnosis has been established after dermatologic consultation.

Geriatrics:
The clinical pharmacology of methotrexate has not been well studied in older individuals. Due to
diminished hepatic and renal function, as well as decreased folate stores in this population,
relatively low doses should be considered, and these patients should be closely monitored for
early signs of toxicity.

Pediatrics:
Safety and effectiveness in pediatric patients have not been established, other than in cancer
chemotherapy.

CONTRAINdications

• Patients who are hypersensitive to this drug or to any ingredient in the formulation or
component of the container. For a complete listing, see the DOSAGE FORMS,
COMPOSITION AND PACKAGING section.

• Pregnancy: Methotrexate can cause fetal death, embryotoxicity, abortion or teratogenic
effects when administered to a pregnant woman. Methotrexate is contraindicated in
pregnant patients with psoriasis or rheumatoid arthritis and should be used in the
treatment of neoplastic diseases only when the potential benefit outweighs the risk to the
fetus.

• Women of childbearing potential should not be started on methotrexate until pregnancy is
excluded and should be fully counselled on the serious risk to the fetus should they
become pregnant while undergoing treatment. Pregnancy should be avoided if either
partner is receiving methotrexate. The optimal time interval between the cessation of
methotrexate treatment of either partner and pregnancy has not been clearly established.
Published literature recommendations for time intervals vary from 3 months to one year
(see WARNINGS AND PRECAUTIONS).

• Because of the potential for serious adverse reactions in breast fed infants, it is
contraindicated in nursing mothers.

• Methotrexate formulations and diluents containing preservatives must not be used for
intrathecal or high dose methotrexate therapy.

- Methotrexate is contraindicated in patients with psoriasis or rheumatoid arthritis in the following situations:
  - Alcoholism, alcoholic liver disease or other chronic liver disease.
  - Overt or laboratory evidence of immunodeficiency syndromes.
  - Pre-existing blood dyscrasias, such as bone marrow hypoplasia, leucopenia, thrombocytopenia or significant anemia.

- Methotrexate injection formulations containing the preservative benzyl alcohol are not recommended for use in neonates (children less than one month of age). There have been reports of fatal ‘gasing syndrome’ in neonates following the administration of intravenous solutions containing the preservative benzyl alcohol. Symptoms include a striking onset of gasping respiration, hypotension, bradycardia and cardiovascular collapse.

**WARNINGS AND PRECAUTIONS**

<table>
<thead>
<tr>
<th>Serious Warnings and Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Methotrexate should be used only by physicians whose knowledge and experience includes the use of antimetabolite therapy (see INDICATIONS AND CLINICAL USE).</td>
</tr>
<tr>
<td>- Methotrexate injection containing benzyl alcohol must not be used for intrathecal, intraventricular, or high dose therapy (see DOSAGE AND ADMINISTRATION).</td>
</tr>
<tr>
<td>- Serious Toxic Reactions (see General section below).</td>
</tr>
<tr>
<td>- Use in pregnancy: Methotrexate has been reported to cause fetal death and/or congenital anomalies (see Special Populations, Pregnant Women section below). Pregnant patients with psoriasis or rheumatoid arthritis should not receive methotrexate (see CONTRAINDICATIONS).</td>
</tr>
</tbody>
</table>

**General**
Because of the possibility of serious toxic reactions (which can be fatal), methotrexate should be used only in life-threatening neoplastic diseases, or in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease that is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis and rheumatoid arthritis. Because of the possibility of serious toxic reactions the patient should be informed by the physician of the risks involved and should be under a physician’s constant supervision.

The use of methotrexate high dose regimens recommended for osteosarcoma requires meticulous
care (see DOSAGE AND ADMINISTRATION). High dosage regimens for other neoplastic diseases are investigational and a therapeutic advantage has not been established.

Methotrexate has the potential for serious toxicity. Toxic effects may be related in frequency and severity to dose or frequency of administration but have been seen at all doses. Because they can occur at any time during therapy, it is necessary to follow patients on methotrexate closely. Most adverse reactions are reversible if detected early. When such reactions do occur, the drug should be reduced in dosage or discontinued and appropriate corrective measures should be taken. If necessary, this could include the use of leucovorin calcium and/or acute, intermittent hemodialysis with a high-flux dialyzer (see OVERDOSAGE). If methotrexate therapy is re-instituted, it should be carried out with caution, with adequate consideration of further need for the drug and with increased alertness as to possible recurrence of toxicity.

Methotrexate exits slowly from third space compartments (e.g., pleural effusions or ascites). This results in a prolonged terminal plasma half-life and unexpected toxicity. In patients with significant third space accumulations, it is advisable to evacuate the fluid before treatment and to monitor plasma methotrexate levels.

Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia and gastrointestinal toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some non-steroidal anti-inflammatory drugs (NSAIDs) (see DRUG INTERACTIONS).

Bone marrow and mucosal toxicity of methotrexate depend on: dose and duration of exposure of high levels (> 2x10^{-8} mol/L (0.02 micromolar)) of methotrexate. Since the critical time factor has been defined for these organs as being 42 hours in humans, this has the following implications:

- When high doses of methotrexate are employed (>1g/m^2), drug levels in serum should be monitored;
- When drug levels exceeding (2x10^{-8} mol/L (0.02 micromolar)) the above for > 42 hours may forecast significant toxicity;
- When toxicity can be minimized by appropriate administration of leucovorin calcium;
- When high-dose methotrexate (HDMTX) is employed, it is imperative to alkalinise the urine in order to prevent crystallisation of methotrexate and its 7-hydroxy metabolite in the urine, which may lead to acute renal failure.

Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.

Methotrexate should be used with extreme caution in the presence of debility.

**Drug Interactions with Proton Pump Inhibitors (PPI)**
Use caution when administering high-dose methotrexate to patients receiving proton pump
inhibitor (PPI) therapy. Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydromethotrexate, possibly leading to methotrexate toxicities. In two of these cases, delayed methotrexate elimination was observed when high-dose methotrexate was co-administered with PPIs, but was not observed when methotrexate was co-administered with ranitidine. However, no formal drug interaction studies of methotrexate with ranitidine have been conducted.

Carcinogenesis and Mutagenesis
Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted.

Like other cytotoxic drugs, methotrexate may induce "tumour lysis syndrome" in patients with rapidly growing tumours. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication.

No controlled human data exist regarding the risk of neoplasia with methotrexate. Methotrexate has been evaluated in a number of animal studies for carcinogenic potential with inconclusive results. Although there is evidence that methotrexate causes chromosomal damage to animal somatic cells and human bone marrow cells, the clinical significance remains uncertain. Assessment of the carcinogenic potential of methotrexate is complicated by conflicting evidence of an increased risk of certain tumours in rheumatoid arthritis. Benefit should be weighed against this potential risk before using methotrexate alone or in combination with other drugs, especially in children or young adults.

Also, see TOXICOLOGY.

Gastrointestinal
If vomiting, diarrhea, or stomatitis occurs, resulting in dehydration, methotrexate should be discontinued until recovery occurs. Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise, hemorrhagic enteritis and death from intestinal perforation may occur. Methotrexate should be used with extreme caution in the presence of peptic ulcer disease or ulcerative colitis.

Hematologic
Methotrexate should be used with caution in patients with impaired bone marrow function and previous or concomitant wide field radiotherapy. Methotrexate may produce marked bone marrow depression with resultant anemia, aplastic anemia, pancytopenia, leucopenia, neutropenia and/or thrombocytopenia. In patients with malignancy and pre-existing hematopoietic impairment, the drug should be used with caution, if at all. In controlled clinical trials in rheumatoid arthritis (n=128), leucopenia (WBC < 3000/mm³) was seen in 2 patients,
thrombocytopenia (platelets < 1000000/mm³) in 6 patients, and pancytopenia in 2 patients.

In psoriasis and rheumatoid arthritis, methotrexate should be stopped immediately if there is a significant drop in blood counts. In the treatment of neoplastic diseases, methotrexate should be continued only if the potential benefit warrants the risk of severe myelosuppression. Patients with profound granulocytopenia and fever should be evaluated immediately and usually require parenteral broad-spectrum antibiotic therapy.

**Hepatic/Biliary/Pancreatic**

Methotrexate has the potential for acute and chronic hepatotoxicity. Acutely, liver enzyme elevations are frequently seen after methotrexate administration and are usually not a reason for modification of methotrexate therapy. Liver enzyme elevations are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. Persistent liver abnormalities, and/or decrease of serum albumin may be indicators of serious liver toxicity. Chronic toxicity is potentially fatal; it generally has occurred after prolonged use (generally two years or more) and after a total cumulative dose of at least 1.5 grams. Liver biopsy after sustained use often shows histologic changes, and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. Periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population. In studies in psoriatic patients, hepatotoxicity appeared to be a function of total cumulative dose and appeared to be enhanced by alcoholism, obesity, diabetes and advanced age. An accurate incidence rate has not been determined; the rate of progression and reversibility of lesions is not known. Special caution is indicated in the presence of pre-existing liver damage or impaired hepatic function.

In psoriasis, liver damage and function tests, including serum albumin and prothrombin time, should be performed several times prior to dosing, but are often normal in the face of developing fibrosis or cirrhosis. These lesions may be detectable only by biopsy.

The usual recommendation is to obtain a liver biopsy: 1) before the start of therapy or shortly after initiation of therapy (4-8 weeks); 2) after a total cumulative dose of 1.5 grams; and 3) after each additional 1.0 to 1.5 grams. Moderate fibrosis or any cirrhosis normally leads to discontinuation of the drug; mild fibrosis normally suggests a repeat biopsy in 6 months. Milder histologic findings such as fatty change and low grade portal inflammation are relatively common pre-therapy. Although these mild changes are usually not a reason to avoid or discontinue methotrexate therapy, the drug should be used with caution.

Clinical experience with liver disease in rheumatoid arthritis is limited, but the same risk factors would be anticipated. Liver function tests are also usually not reliable predictors of histological changes in this population.

In rheumatoid arthritis, advanced age at first use of methotrexate and increasing duration of therapy have been reported as risk factors for hepatotoxicity. Persistent abnormalities in liver
function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid population. Liver function tests should be performed at baseline and at 4-8 week intervals in patients receiving methotrexate for rheumatoid arthritis. Pretreatment liver biopsy should be performed for patients with a history of excessive alcohol consumption, persistently abnormal baseline liver function test values, or chronic hepatitis B or C infection. During therapy, liver biopsy should be performed if there are persistent liver function test abnormalities, or there is a decrease in serum albumin below the normal range (in the setting of well controlled rheumatoid arthritis).

If the results of a liver biopsy show mild changes (Roenigk grades I, II, IIIa), methotrexate may be continued and the patient monitored according to the recommendations listed above. Methotrexate should be discontinued in any patient who displays persistently abnormal liver function tests and refuses liver biopsy, or in any patient whose liver biopsy shows moderate to severe changes (Roenigk grade IIIb or IV).

There is a combined reported experience in 217 rheumatoid arthritis patients with liver biopsies both before and during treatment (after a cumulative dose of at least 1500 mg) and in 714 patients with a biopsy only during treatment. There are 64 (7%) cases of fibrosis and 1 (0.1%) case of cirrhosis. Of the 64 cases of fibrosis, 60 were deemed mild. The reticulin stain is more sensitive for early fibrosis and its use may increase these figures. It is unknown whether even longer use will increase these risks.

**Immune**

Methotrexate should be used with extreme caution in the presence of active infection, and is usually contraindicated in patients with overt or laboratory evidence of immunodeficiency syndromes.

Immunization may be ineffective when given during methotrexate therapy. Immunization with live virus vaccines is generally not recommended. There have been reports of disseminated vaccinia infections after smallpox immunization in patients receiving methotrexate therapy. Hypogammaglobulinemia has been reported rarely.

**Information for Patients**

Patients should be informed of the early signs and symptoms of toxicity, of the need to see their physician promptly if they occur, and the need for close follow-up, including periodic laboratory tests to monitor toxicity.

Both the physician and pharmacist should emphasize to the patient that the recommended dose is taken weekly in rheumatoid arthritis and psoriasis, and that mistaken daily use of the recommended dose has led to fatal toxicity.

Patients should be informed of the potential benefit and risk in the use of Methotrexate Injection USP. The risk of effects on reproduction should be discussed with both male and female patients taking Methotrexate Injection USP.
Neurologic
There have been reports of leukoencephalopathy following intravenous administration of methotrexate to patients who have had craniospinal irradiation. Serious neurotoxicity, frequently manifested as generalized or focal seizures, has been reported with unexpectedly increased frequency among pediatric patients with acute lymphoblastic leukemia who were treated with intermediate-dose intravenous methotrexate (1 g/m²). Symptomatic patients were commonly noted to have leukoencephalopathy and/or microangiopathic calcifications on diagnostic imaging studies. Chronic leukoencephalopathy has also been reported in patients with osteosarcoma who received repeated doses of high-dose methotrexate with leucovorin rescue even without cranial irradiation. Discontinuation of methotrexate does not always result in complete recovery.

A transient acute neurologic syndrome has been observed in patients treated with high dosage regimens. Manifestations of this neurologic disorder may include behavioural abnormalities, focal sensorimotor signs, including transient blindness and abnormal reflexes. The exact cause is unknown.

After the intrathecal use of methotrexate, the central nervous system toxicity which may occur can be classified as follows: chemical arachnoiditis manifested by such symptoms as headache, back pain, nuchal rigidity, and fever; paresis, usually transient, manifested by paraplegia associated with involvement with one or more spinal nerve roots; leukoencephalopathy manifested by confusion, irritability, somnolence, ataxia, dementia, and occasionally major convulsions.

Intravenous administration of methotrexate may also result in acute encephalitis and acute encephalopathy with fatal outcome.

Cases of severe neurological adverse reactions that ranged from headache to paralysis, coma and stroke-like episodes have been reported mostly in juveniles and adolescents given methotrexate in combination with cytarabine.

Renal
Methotrexate therapy in patients with impaired renal function should be undertaken with extreme caution, and at reduced dosages, because renal dysfunction will prolong methotrexate elimination. Methotrexate may cause renal damage that may lead to acute renal failure. High doses of methotrexate used in the treatment of osteosarcoma may cause renal damage leading to acute renal failure.

Nephrotoxicity is due primarily to the precipitation of methotrexate and 7-hydroxymethotrexate in the renal tubules. Close attention to renal function including adequate hydration, urine alkalization and measurement of serum methotrexate and creatinine levels are essential for safe administration.

Respiratory
Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis is a
potentially dangerous lesion, which may occur at any time during therapy and which has been reported at low doses. It is not always fully reversible and fatalities have been reported. Pulmonary symptoms (especially a dry non-productive cough) or a non-specific pneumonitis occurring during methotrexate therapy may be indicative of a potentially dangerous lesion and require interruption of treatment and careful investigation. Although clinically variable, the typical patient with methotrexate-induced lung disease presents with fever, cough, dyspnea, hypoxemia, and an infiltrate on chest X-ray; infection (including pneumonia) needs to be excluded. This lesion can occur at all dosages.

Pneumonia (in some cases leading to respiratory failure) may occur. Potentially fatal opportunistic infections, especially *Pneumocystis carinii* pneumonia, may occur with methotrexate therapy. When a patient presents with pulmonary symptoms, the possibility of *Pneumocystis carinii* should be considered.

**Sexual Function/Reproduction**
Methotrexate causes embryotoxicity, abortion, and fetal defects in humans. It has also been reported to cause impairment of fertility, oligospermia and menstrual dysfunction in humans, during and for a short period after cessation of therapy.

See TOXICOLOGY.

**Skin**
Severe, occasionally fatal, dermatologic reactions, including toxic epidermal necrolysis (Lyell’s Syndrome), Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis and erythema multiforme have been reported in children and adults within days of oral methotrexate administration. Reactions were noted after single or multiple, low, intermediate or high doses of methotrexate in patients with neoplastic and non-neoplastic diseases. Recovery has been reported with discontinuation of therapy.

Lesions of psoriasis may be aggravated by concomitant exposure to ultraviolet radiation. Radiation dermatitis and sunburn may be "recalled" by the use of methotrexate.

**Special Populations**
**Pregnant Women:** Methotrexate can cause fetal death, embryotoxicity, abortion, or teratogenic effects when administered to a pregnant woman. Methotrexate is contraindicated in pregnant patients with psoriasis or rheumatoid arthritis and should be used in the treatment of neoplastic diseases only when the potential benefit outweighs the risk to the fetus. Women of childbearing potential should not be started on methotrexate until pregnancy is excluded and should be fully counselled on the serious risk to the fetus should they become pregnant while undergoing treatment. Pregnancy should be avoided if either partner is receiving methotrexate. The optimal time interval between the cessation of methotrexate treatment of either partner and pregnancy has not been clearly established. Published literature recommendations for time intervals vary from 3 months to one year.
Nursing Women: Because of the potential for serious adverse reactions from methotrexate in breast fed infants, methotrexate is contraindicated in nursing mothers.

Pediatrics: Safety and effectiveness in pediatric patients have not been established, other than in cancer chemotherapy.

Methotrexate injection formulations containing the preservative benzyl alcohol are not recommended for use in neonates (children less than one month of age). There have been reports of fatal ‘gasping syndrome’ in neonates following the administration of intravenous solutions containing the preservative benzyl alcohol. Symptoms include a striking onset of gasping respiration, hypotension, bradycardia and cardiovascular collapse.

Geriatrics: The clinical pharmacology of methotrexate has not been well studied in older individuals. Due to diminished hepatic and renal function, as well as decreased folate stores in this population, relatively low doses should be considered, and these patients should be closely monitored for early signs of toxicity.

Monitoring and Laboratory Tests

General: Patients undergoing methotrexate therapy should be closely monitored so that toxic effects are detected promptly. Baseline assessment should include a complete blood count (CBC) with differential and platelet counts, hepatic enzymes, renal function tests, and a chest X-ray. During therapy of rheumatoid arthritis and psoriasis, monitoring of these parameters is recommended: hematology at least monthly, and hepatic enzyme levels and renal function every 1 to 2 months. More frequent monitoring is usually indicated during antineoplastic therapy. During initial or changing doses, or during periods of increased risk of elevated methotrexate blood levels (e.g., dehydration), more frequent monitoring may also be indicated.

Liver:
Liver biopsies prior to methotrexate therapy are not indicated routinely. Liver function tests (LFTs) should be determined prior to the initiation of therapy with methotrexate and they should be monitored regularly throughout therapy. A relationship between abnormal liver function tests and fibrosis or cirrhosis of the liver has not been established. Transient liver function test abnormalities are observed frequently after methotrexate administration and are usually not cause for modification of methotrexate therapy. Persistent liver function test abnormalities just prior to dosing and/or depression of serum albumin may be indicators of serious liver toxicity and require evaluation.

Respiratory:
Pulmonary function tests may be useful if methotrexate-induced lung disease is suspected, especially if baseline measurements are available.
Methotrexate Injection USP

**Serum Level Monitoring:**
Serum methotrexate level monitoring can significantly reduce methotrexate toxicity and mortality.

Patients subject to the following conditions are predisposed to developing elevated or prolonged methotrexate levels and benefit from routine monitoring of levels: eg, pleural effusion, ascites, gastrointestinal tract obstruction, previous cisplatin therapy, dehydration, aciduria, impaired renal function.

Some patients may have delayed methotrexate clearance in the absence of these features. It is important that patients be identified within 48 hours since methotrexate toxicity may not be reversible if adequate leucovorin rescue is delayed for more than 42 to 48 hours.

The method of monitoring methotrexate concentrations varies from institution to institution. Monitoring of methotrexate concentrations should include determination of a methotrexate level at 24, 48, or 72 hours, and assessment of the rate of decline in methotrexate concentrations (to determine how long to continue leucovorin rescue).

**ADVERSE REACTIONS**

**Adverse Drug Reaction Overview**
In general, the incidence and severity of acute side effects are related to dose, frequency of administration, and the duration of the exposure to significant blood levels of methotrexate to the target organs. The most serious reactions are discussed in WARNINGS AND PRECAUTIONS. That section should also be consulted when looking for information about adverse reactions with methotrexate.

- Some of the effects mentioned in this section, such as dizziness and fatigue, may affect the ability to drive or operate machinery.
- The most frequently reported adverse reactions include ulcerative stomatitis, leucopenia, nausea, and abdominal distress. Other frequently reported adverse effects are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection.

**Adverse Drug Reactions by Organ System**
Adverse reactions that have been reported with methotrexate are listed below alphabetically by organ system. In the oncology setting, concomitant treatment and the underlying disease make specific attribution of a reaction to methotrexate difficult.

- **Alimentary System**: Gingivitis, stomatitis, enteritis, anorexia, nausea, vomiting, diarrhea, hematemesis, melena, gastrointestinal ulceration and bleeding, pancreatitis.
- **Cardiovascular**: Pericarditis, pericardial effusion, hypotension, and
thromboembolic events (including arterial thrombosis, cerebral thrombosis, deep vein thrombosis, retinal vein thrombosis, thrombophlebitis, and pulmonary embolus).

**Central Nervous System:** Headaches, dizziness, drowsiness, speech impediment including dysarthria and aphasia; hemiparesis, paresis and convulsions have also occurred following administration of methotrexate. Following low doses, there have been occasional reports of transient subtle cognitive dysfunction, mood alteration, or unusual cranial sensations, leucoencephalopathy, or encephalopathy.

**Eye Disorders:** Conjunctivitis, blurred vision, serious visual changes of unknown etiology, and transient blindness/vision loss.

**Hematopoietic:** Methotrexate can suppress hematopoiesis and cause anemia, leucopenia, and/or thrombocytopenia. Hypogammaglobulinemia has been reported rarely (see WARNINGS AND PRECAUTIONS - Immune). Lymphadenopathy and lymphoproliferative disorders (including reversible), pancytopenia, neutropenia and agranulocytosis and eosinophilia have also been observed.

**Hepatobiliary Disorders:** Hepatotoxicity, acute hepatitis, chronic fibrosis and cirrhosis, decrease in serum albumin, liver enzyme elevations, hepatic failure.

**Infection:** There have been case reports of sometimes fatal sepsis, sepsis, opportunistic infections, including fatal infections in patients receiving methotrexate therapy for neoplastic and non-neoplastic diseases. *Pneumocystis carinii* pneumonia was the most common infection. Other reported infections included pneumonia, nocardiosis, histoplasmosis, cryptococcosis, *Herpes zoster*, *H. simplex* hepatitis and disseminated *H. simplex* and cytomegalovirus infection, including cytomegaloviral pneumonia.

**Musculoskeletal, Connective Tissue, and Bone Disorders:** Stress fractures.

**Pulmonary System:** Respiratory fibrosis, pharyngitis and interstitial pneumonitis deaths have been reported; chronic interstitial obstructive pulmonary disease and alveolitis have occasionally occurred.

**Skin:** Erythematous rashes, pruritus, urticaria, photosensitivity, pigmenitary changes, alopecia, ecchymosis, telangiectasia, acne, furunculosis, erythema multiforme, toxic epidermal necrolysis (Lyell’s Syndrome), Stevens-Johnson Syndrome, skin necrosis, exfoliative dermatitis, and painful erosion of psoriatic plaques.

**Urogenital System:** Severe nephropathy or renal failure, azotemia, dysuria, cystitis,
hematuria; defective oogenesis or spermatogenesis, transient oligospermia, menstrual dysfunction, vaginal discharge and gynecomastia; infertility, abortion, fetal defects, loss of libido/impotence. Proteinuria has also been observed.

Rarer reactions: Related to or attributed to the use of methotrexate such as nodulosis, vasculitis, herpes zoster, sepsis, arthralgia/myalgia, diabetes, osteoporosis, sudden death, lymphoma, reversible lymphomas, tumour lysis syndrome, soft tissue necrosis, aplastic anemia, fetal death and osteonecrosis. A few cases of anaphylactoid reactions have been reported.

Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate, and thus may not require cytotoxic treatment. Discontinue methotrexate first and if the lymphoma does not regress, appropriate treatment should be instituted.

Other Adverse Drug Reactions
Adverse Reactions Reported in Rheumatoid Arthritis
Incidence greater than 10%: elevated liver enzymes 15%, nausea/vomiting 10%.
Incidence 3% to 10%: stomatitis, thrombocytopenia.
Incidence 1% to 3%: rash/pruritus/dermatitis, alopecia, diarrhea, dizziness, leucopenia and pancytopenia.

Adverse Reactions in Psoriasis
The adverse reaction rates reported are very similar to those in the rheumatoid arthritis studies. Rarely, painful psoriatic plaque erosions may appear.

Abnormal Hematologic and Clinical Chemistry Findings
Abnormal hematologic and clinical chemistry findings are discussed in WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests.

DRUG INTERACTIONS

Drug-Drug Interactions

The drugs listed below are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Nonsteroidal anti-inflammatory drugs should not be administered prior to or concomitantly with the high doses of methotrexate used in the treatment of osteosarcoma. Concomitant
administration of some NSAIDs with high dose methotrexate therapy has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and gastrointestinal toxicity.

Caution should be used when NSAIDs and salicylates are administered concomitantly with lower doses of methotrexate. These drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, and may enhance its toxicity by increasing methotrexate levels.

In treating rheumatoid arthritis with methotrexate, acetyl salicylic acid (ASA), NSAIDs, and/or low dose steroids may be continued.

The possibility of increased toxicity with concomitant use of NSAIDs including salicylates has not been fully explored. Steroids may be reduced gradually in patients who respond to methotrexate. Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents has not been studied and may increase the incidence of adverse effects.

Despite the potential interactions, studies of methotrexate in patients with rheumatoid arthritis have usually included concurrent use of constant dosage regimens of NSAIDs without apparent problems. It should be appreciated however, that the doses used in rheumatoid arthritis (7.5 to 15 mg/week) are somewhat lower than those used in psoriasis and that larger doses could lead to unexpected toxicity.

**Leflunomide**
Methotrexate in combination with leflunomide may increase the risk of pancytopenia.

**Drugs Highly Bound to Plasma Proteins**
Methotrexate is partially bound to serum albumin, and toxicity may be increased because of displacement by certain drugs, such as salicylates, phenylbutazone, phenytoin and sulfonamides.

**Probenecid**
Renal tubular transport is also diminished by probenecid; use of methotrexate with this drug should be carefully monitored.

**Nephrotoxic Drugs**
In the treatment of patients with osteosarcoma, caution must be exercised if high-dose methotrexate is administered in combination with a potentially nephrotoxic chemotherapeutic agent (e.g., cisplatin). Methotrexate clearance is decreased by cisplatinum.

Although not documented, other nephrotoxic drugs such as aminoglycosides, amphotericin B and cyclosporin could theoretically increase methotrexate toxicity by decreasing its elimination.
Penicillins and Sulfonamides
Penicillins and sulfonamides may reduce the renal clearance of methotrexate; hematologic and gastrointestinal toxicity have been observed in combination with methotrexate.

Oral Antibiotics
Oral antibiotics such as tetracycline, chloramphenicol, and non-absorbable broad spectrum antibiotics, may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria. For example: neomycin, polymyxin B, nystatin and vancomycin decrease methotrexate absorption, whereas kanamycin increases methotrexate absorption.

Trimethoprim/sulfamethoxazole has been reported rarely to increase bone marrow suppression in patients receiving methotrexate, probably by decreased tubular secretion and/or an additive antifolate effect.

Theophylline
Methotrexate may decrease the clearance of theophylline; theophylline levels should be monitored when used concurrently with methotrexate.

Mercaptopurine
Methotrexate increases the plasma levels of mercaptopurine. Combination of methotrexate and mercaptopurine may therefore require dose adjustment.

Vitamins
Vitamin preparations containing folic acid or its derivatives may decrease responses to systemically administered methotrexate. Preliminary animal and human studies have shown that small quantities of intravenously administered leucovorin enter the cerebrospinal fluid (CSF) primarily as 5-methyl tetrahydrofolate and, in humans, remain 1 - 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. However, high doses of leucovorin may reduce the efficacy of intrathecally administered methotrexate.

In patients with rheumatoid arthritis or psoriasis, folic acid or folinic acid may reduce methotrexate toxicities such as gastrointestinal symptoms, stomatitis, alopecia and elevated liver enzymes.

Before taking a folate supplement, it is advisable to check B₁₂ levels, particularly in adults over the age of 50, since folate administration can mask symptoms of B₁₂ deficiency.

Folate deficiency states may increase methotrexate toxicity.

The formulation contains benzyl alcohol as preservative and must not be used for intrathecal, intraventricular, or high dose therapy.
Radiotherapy
Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.

Hepatoxins
The potential for increased hepatotoxicity when methotrexate is administered with other hepatotoxic agents has not been evaluated. However, hepatotoxicity has been reported in such cases. Therefore, patients receiving concomitant therapy with methotrexate and other potential hepatotoxic agents (e.g., leflunomide, azathioprine, sulfasalazine, retinoids) should be closely monitored for possible increased risk of hepatotoxicity.

Cytarabine
Methotrexate given concomitantly with cytarabine may increase the risk of severe neurologic adverse events such as headache, paralysis, coma and stroke-like episodes (see WARNINGS AND PRECAUTIONS – Neurologic).

Proton Pump Inhibitors (PPI)
Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitor (PPI) therapy. Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydromethotrexate, possibly leading to methotrexate toxicities. In two of these cases, delayed methotrexate elimination was observed when high-dose methotrexate was co-administered with PPIs, but was not observed when methotrexate was co-administered with ranitidine. However, no formal drug interaction studies of methotrexate with ranitidine have been conducted.

Drug-Food Interactions
The bioavailability of orally administered methotrexate is reduced by food, particularly milk products.

DOSAGE AND ADMINISTRATION

Neoplastic Diseases

Dosing Considerations

- Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit.

- Methotrexate Injection USP may be given by the intramuscular, intravenous, intra-arterial routes. The formulation contains benzyl alcohol as preservative and must not be used for intrathecal, intraventricular, or high dose therapy.
• Methotrexate Injection USP may only be administered by physicians experienced in the treatment of neoplasia. The oncologist should consult the current literature for the treatment regimen to be used. Typical dosages reported in the literature for the following malignancies are listed in the following section.

**Recommended Dose and Dosage Adjustment**

**Breast Cancer**
The initial doses of CMF will be cyclophosphamide 100 mg/m² PO days 1 through 14, Methotrexate Injection USP 40 mg/m² IV day 1, 8, and 5 - Fluourouracil 600 mg/m² IV day 1, 8. Cycle length will be 28 days ("2 weeks-on, 2 weeks-off"). In patients over 60 years of age, the dosage of Methotrexate Injection USP will be 30 mg/m² IV day 1, 8.

If total bilirubin exceeds 1.5 mg/dL, decrease the dose of Methotrexate Injection USP only by 50%.

**Bladder Cancer**
Typical dosage regimens for bladder cancer are the CMV Regimen and the “M-VAC Regimen” which are represented in the following tables.

### Table 1 - CMV Regimen*

<table>
<thead>
<tr>
<th>Drugs**</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Cisplatin‡</td>
<td>100</td>
</tr>
<tr>
<td>Vinblastine</td>
<td>4</td>
</tr>
<tr>
<td>Methotrexate***</td>
<td>30</td>
</tr>
</tbody>
</table>

* All doses in mg/m² with cycles repeated on day 22.

**Patients > 70 years old receive 80% of all doses; if vomiting persists to day 8, no drug is given.

‡For each cycle adjust cisplatin to 100% for Ccr >60 mL/min; 50% of dose for Ccr 50-60 mL/min; none for Ccr <50 mL/min.

***No drug for a decrease on day 8 of >30 mL/min compared to day 1 or Ccr <50 mL/min or Cr >1.8 mg/dL.

†Major dose modifications for both drugs depending on myelosuppression.

### Table 2 - M-VAC Regimen*

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate</td>
<td>30</td>
</tr>
<tr>
<td>Vinblastine</td>
<td>3</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>30</td>
</tr>
<tr>
<td>Cisplatin</td>
<td></td>
</tr>
</tbody>
</table>

*All doses in mg/m² with cycles repeated every 28-32 days.

**Patients having prior pelvic irradiation equivalent to > 2500 rad in 5 days, reduce the dose of Doxorubicin 15 mg/m².

***No doses given when the WBC < 2500 cells/mm³, platelets >100,000 cells/mm³, or mucositis present.
**Head and Neck Cancer**

Methotrexate remains the standard of therapy for patients with recurrent or metastatic disease. It has been given in a wide variety of doses and schedules (a few of which are represented in the table below).

<table>
<thead>
<tr>
<th>Methotrexate Injection USP Schedule*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8 mg/kg every 4 days IV</td>
</tr>
<tr>
<td>25 - 50 mg every 4 to 7 days</td>
</tr>
<tr>
<td>60 mg/m² weekly IV or 40 mg/m² biweekly IV</td>
</tr>
<tr>
<td>40 - 60 mg/m² weekly IV</td>
</tr>
<tr>
<td>80 mg/m² for 30 h every 2 weeks with escalation to toxicity</td>
</tr>
<tr>
<td>40 mg/m² weekly IV</td>
</tr>
<tr>
<td>40-200 mg/m² IV on days 1, 4 weekly; Leucovorin on days 2, 5</td>
</tr>
<tr>
<td>60 mg/m² IV weekly</td>
</tr>
</tbody>
</table>

* excerpt from Devita, et al: CANCER 3rd Ed, p. 496

For palliation of patients with advanced incurable disease and acceptable renal function, it is appropriate to begin oral or intravenous methotrexate with weekly doses of 40-50 mg/m² or biweekly doses of 15 to 20 mg/m² and escalate the dose in weekly increments until either mild toxicity or therapeutic response is achieved.

**Gastric Cancer**

A regimen used in a clinical trial in Belgium in patients with resectable gastric cancer follows: methotrexate (1.5 g/m² IV day 1, + 5-Fluorouracil (1.5 g/m² IV) + Leucovorin (15 mg/m² orally or IV every 6 hours for 72 hours) + doxorubicin (30 mg/m² IV, day 15). The schedule is repeated on day 29 for 6 cycles.

**Choriocarcinoma and similar trophoblastic diseases**

Methotrexate Injection USP is administered intramuscularly in doses of 15 to 30 mg daily for a 5 day course. Such courses are usually repeated for 3 to 5 times, as required, with rest periods of one or more weeks interposed between courses, until any manifesting toxic symptoms subside. The effectiveness of therapy is ordinarily evaluated by 24 hour quantitative analysis of urinary chorionic gonadotrophin hormone (beta-HCG), which should return to normal or less than 50 IU/24 hours usually after the third or fourth course, and usually be followed by a complete resolution of measurable lesions in four to six weeks. One to two courses of methotrexate after normalization of beta-HCG is usually recommended. Before each course of the drug, careful clinical assessment is essential. Cyclic combination therapy of methotrexate with other anti-tumour drugs has been reported as being useful.

Since hydatiform mole may precede by choriocarcinoma, prophylactic chemotherapy with
methotrexate has been recommended.

Chorioadenoma dresuens is considered to be an invasive form of hydatiform mole. Methotrexate Injection USP is administered in these disease states in doses similar to those recommended for choriocarcinoma.

**Lymphomas**

In Burkitt's tumour, Stages I-II, methotrexate has produced prolonged remissions in some cases. Recommended dosage is 10 to 25 mg/day orally for 4 to 8 days. In Stage III, methotrexate is commonly given concomitantly with other anti-tumour agents. Treatment in all stages usually consists of several courses of the drug interposed with 7 to 10 day rest periods. Lymphosarcomas in Stage III may respond to combined drug therapy with methotrexate given in doses of 0.625 to 2.5 mg/kg daily.

The treatment of choice for localized histologically aggressive lymphoma is primary combination chemotherapy with or without involved-field radiation therapy. Frequently used regimens for intermediate, or high grade NHL that include methotrexate include groups: the ProMACE/MOPP, ProMACE-CytaBOM, Magrath Protocols. Represented in the table below for example, is the ProMACE-CytaBOM Regimen.

<table>
<thead>
<tr>
<th>ProMACE-CytaBOM</th>
<th>Day 1</th>
<th>Day 8</th>
<th>Day 14</th>
<th>Days 15-21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide 650 mg/m² IV</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doxorubicin 25 mg/m² IV</td>
<td></td>
<td>x</td>
<td></td>
<td>No therapy</td>
</tr>
<tr>
<td>Etoposide 120 mg/m² IV</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Cytarabine 300 mg/m² IV</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleomycin 5 mg/m² IV</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vincristine 1.4 mg/m² IV</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Methotrexate 120 mg/m² IV</td>
<td></td>
<td>x</td>
<td></td>
<td>x with leucovorin rescue</td>
</tr>
<tr>
<td>Prednisone 60 mg/m² PO</td>
<td>x-------</td>
<td>--------</td>
<td>--------</td>
<td>------------</td>
</tr>
</tbody>
</table>

Co-trimoxazole 2 PO bid throughout 6 cycles of therapy

In early stage childhood non-Hodgkin's lymphoma, methotrexate is used effectively in combination chemotherapy regimens.

**Mycosis Fungoides (cutaneous T-cell lymphoma)**

Therapy with methotrexate appears to produce a clinical response, in up to 50% of patients treated, but chemotherapy is not curative. Dosage is usually 2.5 to 10 mg daily by mouth for several weeks or months. Dose levels of drug and adjustment of dose regimen by reduction or cessation of drug are guided by patient response and hematologic monitoring. Methotrexate has
also been given intramuscularly in doses of 50 mg once weekly or 25 mg 2 times weekly.

**Leukemia**

Acute lymphoblastic leukemia (ALL) in children and young adolescents is the most responsive to present day chemotherapy. In young adults and older patients, clinical remission is more difficult to obtain and early relapse is more common.

Methotrexate alone or in combination with steroids was used initially for induction of remission in ALL. More recently, corticosteroid therapy in combination with other antileukemic drugs or in cyclic combinations with methotrexate, has appeared to produce rapid and effective remissions. When used for induction, methotrexate in doses of 3.3 mg/m² in combination with 60 mg/m² of prednisone, given daily, produced remission in 50% of patients treated usually within a period of 4 to 6 weeks. Methotrexate in combination with other agents appears to be the drug of choice for securing maintenance of drug-induced remissions. When remission is achieved and supportive care has produced general clinical improvement, maintenance therapy is initiated as follows:

Methotrexate Injection USP is administered 2 times weekly intramuscularly in total weekly doses of 30 mg/m². It has also been given in doses of 2.5 mg/kg intravenously every 14 days. If and when relapse does occur, re-induction of remission can again usually be obtained by repeating the initial induction regimen.

A variety of combination chemotherapy regimens have been used for both induction and maintenance therapy in ALL. The physician should be familiar with recent advances in antileukemic therapy.

**Psoriasis and Rheumatoid Arthritis**

**Dosing Considerations**

- Refer to Neoplastic Diseases – Dosing Considerations
- The patient should be fully informed of the risks involved and should be under constant supervision of the physician (see WARNINGS AND PRECAUTIONS - Information for Patients).
- All dosage schedules should be continually tailored to the individual patient. An initial test dose may be given prior to the regular dosing schedule to detect any extreme sensitivity to adverse effects (see ADVERSE REACTIONS). Maximal myelosuppression usually occurs in seven to ten days.

**Recommended Dose and Dosage Adjustments**

**Psoriasis**

Recommended Starting Dose Schedules

- Weekly single, IM or IV dose schedule: 10 to 25 mg per week until adequate response is achieved.
Dosages in each schedule may be gradually adjusted to achieve optimal clinical response; 30 mg/week should not ordinarily be exceeded.

Once optimal clinical response has been achieved, the dosage schedule should be reduced to the lowest possible amount of drug and to the longest possible rest period. The use of methotrexate may permit the return to conventional topical therapy, which should be encouraged.

**Rheumatoid Arthritis**

Recommended Starting Dosage Schedules

Therapeutic response usually begins within 3 to 6 weeks and the patient may continue to improve for another 12 weeks or more.

**Administration**

**Dilution:**

Methotrexate Injection USP may be diluted with any of the solutions for IV infusion listed below in a concentration range of 0.4 mg/mL to 2 mg/mL. Dilutions should be used within 24 hours when kept at room temperature or in the refrigerator (between 2°C and 8°C). Unused solution should be discarded after this time in order to avoid risk of microbial contamination.

**Solutions:**

- 0.9% Sodium Chloride Injection
- 5% Dextrose Injection
- 4% Dextrose and 0.18% Sodium Chloride Injection
- Ringer's Injection

Since methotrexate is poorly soluble in acid media, use of potassium chloride solution is not advisable.

If a preservative free diluent is used, the solution should be used immediately because of the possibility of microbial growth. It is advisable to protect diluted solutions from light.

It is recommended that the vial remains in the carton until time of use. The Methotrexate Injection USP vial should be inspected for damage and visible signs of leaks. If there are signs of breakage or leakage from the vial, do not use. Incinerate the unopened package.

The undiluted solutions are stable if kept in polypropylene syringes at room temperature or in the refrigerator (between 2°C and 8°C) for up to 30 days.

**Incompatibilities:**

Other drugs should not be mixed with Methotrexate Injection USP in the same infusion bottle.

Methotrexate has been reported to be incompatible with cytarabine, fluorouracil, and
prednisolone sodium phosphate; however, its incompatibility with fluorouracil has been questioned. A mixture of methotrexate with cytarabine and hydrocortisone sodium succinate in various infusion fluids has been reported to be visually compatible for at least 8 hours at 25°C, although precipitation did not occur on storage for several days.

Contact with acidic solutions should be avoided since methotrexate is sparingly soluble in acid media and precipitation may occur.

See WARNINGS AND PRECAUTIONS for clinical incompatibilities.

OVERDOSAGE

In postmarketing experience, overdose with methotrexate has generally occurred with intrathecal administration, although intravenous and intramuscular overdose have also been reported.

Discontinue or reduce dosage at the first sign of ulceration or bleeding, diarrhea, or marked depression of the hematopoietic system. Leucovorin is indicated to diminish the toxicity and counteract the effect of inadvertently administered overdosages of methotrexate. Leucovorin administration should begin as promptly as possible. As the time interval between methotrexate administration and leucovorin initiation increases, the effectiveness of leucovorin in counteracting toxicity decreases. Monitoring of the serum methotrexate concentration is essential in determining the optimal dose and duration of treatment with leucovorin.

In cases of massive overdosage, hydration and urinary alkalinization may be necessary to prevent the precipitation of methotrexate and/or its metabolites in the renal tubules. Generally, neither standard hemodialysis nor peritoneal dialysis has been shown to improve methotrexate elimination. However, effective clearance of methotrexate has been reported with acute, intermittent hemodialysis using a high-flux dialyzer.

There are published case reports of intravenous carboxypeptidase G2 treatment to hasten clearance of methotrexate in cases of overdoses.

For management of a suspected drug overdose, contact your regional Poison Control Centre immediately.

ACTION AND CLINICAL PHARMACOLOGY

**Mechanism of Action**
Methotrexate is a folate antagonist.

Methotrexate inhibits dihydrofolate reductase (DHFR), the enzyme that reduces folic acid to
tetrahydrofolic acid. Tetrahydrofolate must be regenerated via the DHFR-catalyzed reaction in order to maintain the intracellular pool of tetrahydrofolate one-carbon derivatives for both thymidylate and purine nucleotide biosynthesis. The inhibition of DHFR by folate antagonists (methotrexate) results in a deficiency in the cellular pools of thymidylate and purines and thus in a decrease in nucleic acid synthesis. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication.

Methotrexate is most active against rapidly multiplying cells, because its cytotoxic effects occur primarily during the S phase of the cell cycle. Since cellular proliferation in malignant tissues is greater than in most normal tissues, methotrexate may impair malignant growth without irreversible damage to normal tissues. As a result, actively proliferating tissues, such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder, are generally more sensitive to DHFR inhibition effects of methotrexate.

The cytotoxicity of methotrexate results from three important actions: inhibition of DHFR, inhibition of thymidylate synthase, and alteration of the transport of reduced folates. The affinity of DHFR to methotrexate is far greater than its affinity for folic acid or dihydrofolic acid, therefore, large doses of folic acid given simultaneously will not reverse the effects of methotrexate. However, Leucovorin Calcium, a derivative of tetrahydrofolic acid may block the effects of methotrexate if given shortly after the antineoplastic agent. Methotrexate in high doses, followed by leucovorin rescue, is used as a part of the treatment of patients with non-metastatic osteosarcoma.

The original rationale for high dose methotrexate therapy was based on the concept of selective rescue of normal tissues by leucovorin. More recent evidence suggests that high dose methotrexate may also overcome methotrexate resistance caused by impaired active transport, decreased affinity of dihydrofolic acid reductase for methotrexate, increased levels of dihydrofolic acid reductase resulting from gene amplification, or decreased polyglutamination of methotrexate. The actual mechanism of action is unknown.

Methotrexate has immunosuppressive activity. This may be a result of inhibition of lymphocyte multiplication. The mechanisms of action in the management of rheumatoid arthritis of the drug are not known, although suggested mechanisms have included immunosuppressive and/or anti-inflammatory effects.

In psoriasis, the rate of production of epithelial cells in the skin is greatly increased over normal skin. This differential in proliferation rates is the basis for the use of methotrexate to control the psoriatic process.

**Pharmacokinetics**

**Absorption:** Orally administered methotrexate is absorbed rapidly in most, but not all patients and reaches peak serum levels in 1 to 4 hours. Methotrexate is generally completely absorbed following parenteral administration, and after intramuscular injection peak serum concentrations occur in 30 to 60 minutes.
**Distribution:** Methotrexate in serum is approximately 50% protein bound. After intravenous administration, the initial volume of distribution is approximately 0.18 L/kg (18% of body weight) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40% to 80% of body weight). Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given orally or parenterally.

**Metabolism:** After absorption, methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms which can be converted back to methotrexate by hydrolase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate synthases. Small amounts of methotrexate polyglutamates may remain in tissues for extended periods. The retention and prolonged drug action of these active metabolites vary among different cells, tissues and tumours. A small amount of metabolism to 7-hydroxymethotrexate may occur at doses commonly prescribed. The aqueous solubility of 7-hydroxymethotrexate is 3 to 5 fold lower than the parent compound. Methotrexate is partially metabolized by intestinal flora after oral administration.

**Excretion:** Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. Excretion of single daily doses occurs through the kidneys in amounts from 80% to 90% within 24 hours. Repeated daily doses result in more sustained serum levels and some retention of methotrexate over each 24-hour period, which may result in accumulation of the drug within the tissues. The liver cells appear to retain certain amounts of the drug for prolonged periods even after a single therapeutic dose. Methotrexate is retained in the presence of impaired renal function and may increase rapidly in the serum and in the tissue cells under such conditions. Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given orally or parenterally. High concentrations of the drug, when needed, may be attained by direct intrathecal administration.

The terminal half-life reported for methotrexate is approximately 3 to 10 hours for patients receiving treatment for psoriasis, rheumatoid arthritis or low dose antineoplastic therapy (less than 30 mg/m²). For patients receiving high doses of methotrexate, the terminal half-life is 8 to 15 hours.

Methotrexate clearance rates vary widely and are generally decreased at higher doses.

**The formulation contains benzyl alcohol as preservative and must not be used for intrathecal, intraventricular, or high dose therapy.**

**Special Populations and Conditions**

**Nursing Women:** Methotrexate has been detected in human breast milk and is contraindicated during breast feeding. The highest breast milk to plasma concentration ratio reached was 0.08: 1.
STORAGE AND STABILITY

Keep in a safe place out of reach of children.

Store Methotrexate Injection USP vials between 15-25 °C. Protect from light.

Multidose vials ((50 mg/2 mL and 500 mg/20 mL) Methotrexate with benzyl alcohol) should be stored in the refrigerator (between 2°C and 8°C) or at room temperature (between 15°C and 25°C) after the vials are punctured for a maximum of four weeks (30 days). Protect from light. Aseptic techniques should be used when handling punctured vials to avoid contamination.

It is recommended that the vial remains in the carton until time of use. The Methotrexate Injection USP vial should be inspected for damage and visible signs of leaks. If there are signs of breakage or leakage from the vial, do not use. Incinerate the unopened package.

SPECIAL HANDLING INSTRUCTIONS

General:
Individuals who have contact with anti-cancer drugs or work in areas where these drugs are used, may be exposed to these agents in air or through direct contact with contaminated objects. Potential health effects may be reduced by adherence to institutional procedures, published guidelines and local regulations for preparation, administration, transportation and disposal of hazardous drugs.

Safe Handling and Disposal:
Methotrexate Injection USP is a potent anti-neoplastic drug. Good medical practice will minimize exposure of persons involved with frequent handling of this drug as outlined below:

Handling:

1. Methotrexate Injection USP has no vesicant properties and does not show acute toxicity on topical contact with the skin or mucous membranes. However, persons involved with handling cytotoxic drugs should avoid contact with skin and inhalation of airborne particles.

2. Preparation of antineoplastic solutions should be done in a vertical laminar flow hood (Biological Safety Cabinet - Class II).

3. Personnel preparing Methotrexate Injection USP solutions should wear PVC gloves, safety glasses and protective clothing such as disposable gowns and masks.

4. Personnel regularly involved in preparation and handling of antineoplastics should have bi-annual blood examinations.
Disposal:

1. Avoid contact with skin and inhalation of airborne particles by use of PVC gloves and disposable gowns and masks.

2. All needles, syringes, vials and other materials for disposal which have come in contact with Methotrexate Injection USP should be segregated in plastic bags, sealed and marked as hazardous waste. Incinerate at 1000°C or higher. Sealed containers may explode if a tight seal exists.

3. If incineration is not available, rinse all needles, syringes, tubing and other materials for disposal which have come in contact with Methotrexate Injection USP solutions with water and discard in the sewer system with running water.

Rinse vials with the appropriate quantity of water with the aid of a hypodermic syringe. Withdraw the solution and discard in the sewer system with running water. Dispose of rinsed equipment and vials in a safe manner.

Cleaning:
Non-disposable equipment that has come in contact with methotrexate may be rinsed with water and washed thoroughly with soap and water.

Spillage/Contamination:
Wear gloves, mask and protective clothing. Place spilled material in an appropriate container (i.e., cardboard for broken glass) and then in a polyethylene bag; absorb remains with gauze pads or towels; wash area with water and absorb with gauze or towels again and place in bag; seal, double bag and mark as a hazardous waste. Dispose of waste by incineration or by other methods approved for hazardous materials. Personnel involved in clean up should wash with soap and water.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Methotrexate Injection USP is supplied in a carton containing 50 mg and 500 mg of Methotrexate (as the sodium salt) as follows:

- 25 mg/mL methotrexate 50 mg /2 mL (contains preservative) – multidose vials
- 25 mg/mL methotrexate 500 mg /20 mL (contains preservative) – multidose vials

Composition: Methotrexate Injection USP is a sterile, isotonic solution containing: Methotrexate sodium equivalent to 25 mg/mL methotrexate with 2.6 mg/mL sodium chloride and 0.9% v/v benzyl alcohol (preservative), with sodium hydroxide and hydrochloric acid as pH adjusters.

Note: 2 mL vials are available as single vials. 20 mL vials are available as single vials.
Note: 50 mg/2 mL and 500 mg/20 mL Methotrexate Injection USP, with benzyl alcohol (preservative) are supplied as multidose vials. Please see special storage conditions once the vials are punctured.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Methotrexate

Chemical name: N-[4-[[2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid

Molecular formula and molecular mass: $C_{20}H_{22}N_{8}O_5$ (454.45 g/mol)

Structural formula:

![Structural formula of Methotrexate]

Physicochemical properties:

Physical Form: yellow to orange, crystalline powder, resembles the crystalline hydrate form (water content about 9%).

Solubility: practically insoluble in water, dichloroethane, ethanol and diethylether; soluble in dilute acids and alkaline solutions
DETAILED PHARMACOLOGY

Human Pharmacokinetics

Absorption
In adults, oral absorption appears to be dose dependent. Peak serum levels are reached within one to two hours. At doses of 30 mg/m^2 or less, methotrexate is generally well absorbed with a mean bioavailability of about 60%. The absorption of doses greater than 80 mg/m^2 is significantly less, possibly due to a saturation effect.

In leukemic pediatric patients, oral absorption has been reported to vary widely (23% to 95%). A twenty fold difference between highest and lowest peak levels (C_{\text{max}}: 0.11 to 2.3 micromolar after a 20 mg/m^2 dose) has been reported. Significant inter-individual variability has also been noted in time to peak concentration (T_{\text{max}}: 0.67 to 4 hrs after a 15 mg/m^2 dose) and fraction of dose absorbed. The bioavailability of orally administered methotrexate is reduced by food, particularly milk products. The absorption of doses greater than 40 mg/m^2 has been reported to be significantly less than that of lower doses. Methotrexate is generally completely absorbed from parenteral routes of injection. After intramuscular injection, peak serum concentrations occur in 30 to 60 minutes.

Distribution
After intravenous administration, the initial volume of distribution is approximately 0.18 L/kg (18% of body weight) and steady-state volume of distribution is approximately 0.4 to 0.8 L/kg (40% to 80% of body weight). Methotrexate competes with reduced folates for active transport across cell membranes by means of a single carrier-mediated active transport process. At serum concentrations greater than 100 micromolar, passive diffusion becomes a major pathway by which effective intracellular concentrations can be achieved. Methotrexate in serum is approximately 50% protein bound. Laboratory studies demonstrate that it may be displaced from plasma albumin by various compounds including sulfonamides, salicylates, tetracyclines, chloramphenicol, and phenytoin.

Methotrexate does not penetrate the blood-cerebrospinal fluid barrier in therapeutic amounts when given orally or parenterally. High CSF concentrations of the drug may be attained by intrathecal administration. **The formulation contains benzyl alcohol as preservative and must not be used for intrathecal, intraventricular, or high dose therapy.**

In dogs, synovial fluid concentrations after oral dosing were higher in inflamed than uninflamed joints. Although salicylates did not interfere with this penetration, prior prednisone treatment reduced penetration into inflamed joints to the level of normal joints.

Metabolism
After absorption, methotrexate undergoes hepatic and intracellular metabolism to polyglutamated forms, which can be converted back to methotrexate by hydrolase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymidylate syntheses. Small
amounts of methotrexate polyglutamates may remain in tissues for extended periods. The retention and prolonged drug action of these active metabolites vary among different cells, tissues and tumours. A small amount of metabolism to 7-hydroxy methotrexate may occur at doses commonly prescribed. Accumulation of this metabolite may become significant at the high doses used in osteogenic sarcoma. The aqueous solubility of 7-hydroxy methotrexate is 3 to 5 fold lower than the parent compound. Methotrexate is partially metabolized by intestinal flora after oral administration.

**Half-Life**

The terminal half-life reported for methotrexate is approximately three to ten hours for patients receiving treatment for psoriasis, rheumatoid arthritis or low dose antineoplastic therapy (less than 30 mg/m$^2$). For patients receiving high doses of methotrexate, the terminal half-life is eight to fifteen hours.

**Excretion**

Renal excretion is the primary route of elimination and is dependent upon dosage and route of administration. With IV administration, 80% to 90% of the administered dose is excreted unchanged in the urine within 24 hours. There is limited biliary excretion amounting to 10% or less of the administered dose. Enterohepatic recirculation of methotrexate has been proposed.

Renal excretion occurs by glomerular filtration and active tubular secretion. Non-linear elimination due to saturation of renal tubular reabsorption has been observed in psoriatic patients at doses between 7.5 and 30 mg. Impaired renal function, as well as concurrent use of drugs such as weak organic acids that also undergo tubular secretion, can markedly increase methotrexate serum levels. Excellent correlation has been reported between methotrexate clearance and endogenous creatinine clearance.

Methotrexate clearance rates vary widely and are generally decreased at higher doses. Delayed drug clearance has been identified as one of the major factors responsible for methotrexate toxicity. It has been postulated that the toxicity of methotrexate for normal tissues is more dependent upon the duration of exposure to the drug rather than the peak level achieved. When a patient has delayed drug elimination due to compromised renal function, a third space effusion, or other causes, methotrexate serum concentrations may remain elevated for prolonged periods.

The potential for toxicity from high dose regimens or delayed excretion is reduced by the administration of leucovorin calcium during the final phase of methotrexate plasma elimination. Pharmacokinetic monitoring of methotrexate serum concentrations may help identify those patients at high risk for methotrexate toxicity and aid in proper adjustment of leucovorin dosing.
TOXICOLOGY

The acute toxicity (LD$_{50}$) of methotrexate in mice ranges from 65 to 70 mg/kg intravenously and 45 to 90 mg/kg intraperitoneally.

The acute oral toxicity (LD$_{50}$) in rats is 317 mg/kg; subcutaneously, it is 58 mg/kg and intraperitoneally it ranges from 80 to 464 mg/kg.

In a 22 month carcinogenicity study in rats that received methotrexate at doses of 0.1, 0.2 and 0.4 mg/kg/day, 5 days/week every other week, little or no effect of the drug was observed. It has been concluded that methotrexate is apparently remarkably free from toxic effects when otherwise lethal doses are administered utilizing an intermittent dosage schedule providing for a recovery period of 9 days. For example, daily oral doses of 0.4 mg/kg are lethal doses both in dogs and rats when administered for up to two weeks; when 0.5 mg/kg and 0.4 mg/kg doses, respectively, were administered daily five times a week every other week for three months to dogs and ten months to rats, they were found to be essentially without toxicity.

Methotrexate is often used clinically in doses that are nearly toxic and may cause severe depression of all blood cellular elements. Constant supervision is recommended and signs of gastrointestinal ulceration and bleeding, including bleeding from the mouth, bone marrow depression, primarily of the white cell series and alopecia are indications of toxicity. In general, toxicity is in direct proportion to dose and exposure time to methotrexate.

Toxicity of methotrexate to the bone marrow and gastrointestinal epithelium is not so much dependent on dosage as on the duration of exposure of these organs to the drug and its extracellular (plasma) concentration. For bone marrow and gastrointestinal tract, the critical time factor has been defined as about 42 hours and the critical plasma concentration as $2 \times 10^{-8}$ M. Both factors must be exceeded for toxicity to occur to these organs.

Doses of methotrexate resulting in plasma levels in excess of $2 \times 10^{-8}$ M circulating for greater than 42 hours will be toxic to both the bone marrow and gastrointestinal epithelium. This toxicity can be minimized by the appropriate administration of leucovorin calcium.

Methotrexate may be hepatotoxic, particularly at high dosage and with prolonged therapy. Liver atrophy, necrosis, cirrhosis, fatty changes and periportal fibrosis have been reported.
REFERENCES

Anti-neoplastic Chemotherapy


13. Pitman SW and Frei E. Weekly Methotrexate-Calcium Leucovorin rescue: Effect of

14. Rooney TW, Furst De. Comparison of toxicity in Methotrexate (MTX) treated rheumatoid arthritis (RA) patients also taking aspirin (ASA) or other NSAID. Abstract. Arthritis Rheum 29 Suppl 4:S76.


Psoriasis Chemotherapy


25. Rees RB, Bennett JH, Maibach HI, and Arnold HL. Methotrexate for Psoriasis. Arch


**NSAID Interactions**


**Interactions with Radiotherapy**


**Hemodialysis**


**General**


58. Hospira Healthcare Corporation, Product Monograph Methotrexate Injection, USP (10 mg/mL and 25 mg/mL), Control No. 155784, June 27, 2012.
PART III: CONSUMER INFORMATION

Methotrexate Injection USP

This leaflet is part III of a three-part "Product Monograph" published when Methotrexate Injection USP was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Methotrexate Injection USP. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
Methotrexate belongs to a group of medicines known as antimetabolites. It is used in high doses to treat many types of cancers, including breast cancer, Non-Hodgkin's lymphoma and leukemia. At lower doses, it may also be used to treat psoriasis and rheumatoid arthritis.

What it does:
Methotrexate works by blocking an enzyme needed by body cells to live. This interferes with the growth of some cells, such as skin cells in psoriasis that are growing rapidly. In rheumatoid arthritis, methotrexate acts on the inflammatory cells that cause joint swelling. Methotrexate therapy is used to control psoriasis and rheumatoid arthritis but it will not cure them. In cancer, Methotrexate Injection USP works by blocking an enzyme process in cancer cells so that they cannot grow. Some normal cells in the body may be affected as well.

Your doctor may have prescribed methotrexate for another purpose. Ask your doctor if you have any questions about why it has been prescribed for you.

When it should not be used:
Do not take Methotrexate Injection USP if you:

- Are allergic to any component of the drug (see What the nonmedicinal ingredients are). Some of the symptoms of an allergic reaction to methotrexate may include rash, itching or hives on the skin, swelling of the face, lips, tongue or other parts of the body, shortness of breath, wheezing or troubled breathing.
- Have any blood disorders including:
  - bleeding from a lack of blood cells called platelets.
  - low iron in the blood (anemia).
- Have an immune system disorder such as AIDS (autoimmune deficiency syndrome) or HIV, the virus which causes AIDS.
- Have an infection.
- Have severe kidney or liver disorder.
- Suffer from alcoholism or alcoholic liver disease.
- Have a stomach ulcer.

- Have inflammation and bleeding from the rectum, with abdominal pain and diarrhea (ulcerative colitis).
- Are pregnant or breastfeeding.

Methotrexate Injection USP contains benzyl alcohol as preservative. It is not recommended for use in children less than one month of age.

What the medicinal ingredient is:
Methotrexate (meth-o-TREX-ate).

What the nonmedicinal ingredients are:
Benzyl alcohol (preservative), hydrochloric acid, sodium chloride, sodium hydroxide and water for injection.

What dosage forms it comes in:
Methotrexate Injection USP is supplied as follows:
- 50 mg /2 mL (contains preservative) - multidose vials
- 500 mg /20 mL (contains preservative) – multidose vials

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

- You should not plan to have children while taking methotrexate or for a while after stopping treatment. (Talk to your doctor for further details.)
- Use a reliable method of birth control to prevent pregnancy.

Before Using This Medicine

Before you begin treatment with methotrexate, you should talk to your doctor about the good this medicine will do as well as the risks of using it.

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For methotrexate, the following should be considered:

Allergies:
- Tell your doctor if you have ever had any unusual or allergic reaction to methotrexate.

Pregnancy:
- Tell your doctor if you are pregnant or if you plan to have children. There is a good chance that this medicine may cause birth defects if either the male or female is taking it at the time of conception or if it is taken during pregnancy. Methotrexate may cause harm or even death of the fetus. Also, many cancer medicines may cause sterility, which could be permanent. Although sterility is probably rare with this medicine, the possibility should be
kept in mind.

- Be sure that you have discussed this with your doctor before taking this medicine. It is best to use some kind of birth control while you are taking methotrexate. Tell your doctor right away if you think you have become pregnant while taking methotrexate.

Breast-feeding:
- Tell your doctor if you are breast-feeding or if you intend to breast-feed during treatment with this medicine. Because methotrexate may cause serious side effects, breast-feeding is generally not recommended while you are taking it.

Children:
- Newborns and other infants may be more sensitive to the effects of methotrexate. However, in other children it is not expected to cause different side effects or problems than it does in adults.
- Methotrexate Injection USP contains benzyl alcohol as preservative. It is not recommended for use in children less than one month of age.

Older adults:
- Side effects may be more likely to occur in the elderly, who are usually more sensitive to the effects of methotrexate.

Other medicines:
- When you are taking methotrexate, it is important that your doctor know if you are taking any other prescription or nonprescription medicine. They should also be told if you have ever been treated with x-rays or cancer medicines or if you drink alcohol.

Other medical problems:
The presence of other medical problems may affect the use of methotrexate. Tell your doctor if you have any other medical problems, especially:
- Alcohol abuse (or history of)
- Chickenpox (including recent exposure) or Herpes zoster (shingles)
- Colitis
- Disease of the immune system
- Gout (or history of)
- Kidney stones (or history of)
- Infection
- Intestine blockage
- Kidney disease
- Liver disease
- Mouth sores or inflammation
- Stomach ulcer

Precautions while using this medicine
It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to check for unwanted effects.

Do not drink alcohol while taking methotrexate. Alcohol can increase the chance of liver problems.

Some patients who take methotrexate may become more sensitive to sunlight than they are normally. Avoid too much sun exposure and do not use a sunlamp until you see how you react to the sun, especially if you tend to burn easily.

You should not receive certain vaccinations while taking methotrexate. Discuss this with your doctor. Avoid anyone who has had oral polio vaccine for at least six weeks. Do not get close to them or stay in the same room for very long. If this is not possible, wear a mask over your nose and mouth.

Some side effects such as dizziness and fatigue may affect the ability to drive or operate machinery. These activities should be avoided. If you have any concerns, please consult your doctor.

Methotrexate can lower the number of white blood cells in your blood temporarily, increasing the chance of getting an infection. It can also lower the number of platelets, which are necessary for proper blood clotting. If this happens, there are certain precautions you can take, especially when your blood count is low to reduce the risk of infection or bleeding:
- If you can, avoid people with infections. Check with your doctor immediately if you think you are getting an infection or if you get a fever or chills, cough or hoarseness, lower back or side pain, or painful or difficult urination.
- Check with your doctor immediately if you notice any unusual bleeding or bruising; black, tarry stools; blood in urine or stools; or pinpoint red spots on your skin.
- Be careful when using a regular toothbrush, dental floss, or toothpick. Check with your doctor before having any dental work done.
- Do not touch your eyes or the inside of your nose unless you have just washed your hands.
- Be careful not to cut yourself when you are using sharp objects such as scissors or a razor.
- Avoid contact sports or other situations where bruising or injury could occur.

**INTERACTIONS WITH THIS MEDICATION**

Tell your doctor and pharmacist what prescription and nonprescription medications you are taking. Methotrexate may interact with other medicines such as:
- acetyl salicylic acid (ASA) and other pain killers or nonsteroidal anti-inflammatory drugs (NSAIDs)
- some antibiotics (including penicillins and sulfonamides, and medicines to prevent malaria – pyrimethamine)
• some epilepsy treatments
• some cancer treatments
• some vaccines
• some medicines used to lower your cholesterol (including cholesterol
  inhibitors)
• azathioprine (used to prevent transplant organ rejection)
• cytarabine (used to treat leukemia)
• leflunomide (used to treat rheumatoid arthritis)
• mercaptopurine (used to treat leukemia)
• nitrous oxide anaesthesia
• probenecid (used to treat gout)
• retinoid medicines (used to treat acne)
• sulfonylureas (used to treat diabetes)
• sulfasalazine (used to treat Crohn's disease, rheumatoid
  arthritis and ulcerative colitis)
• theophylline (used to treat asthma)
• the vitamin folic acid
• phenytoins
• proton pump inhibitors

The absorption of orally administered methotrexate is reduced by
food, particularly milk products.

It is very important to tell your doctor about all other medicines
you are taking including those you buy without a prescription.
You may need to receive different amounts of your medicine or
you may need to receive different medicines.

Tell any doctor that is treating you that you are taking
methotrexate.

If you have not told your doctor or pharmacist about any of the
above, tell them before you are given methotrexate.

**PROPER USE OF THIS MEDICATION**

Take Methotrexate Injection USP only as directed by your doctor.
Do not take more or less of it, and do not take it more often than
your doctor ordered. The exact amount of medicine you need has
been carefully worked out. Taking too much may increase the
chance of side effects, while taking too little may not improve
your condition.

Methotrexate is often given together with certain other medicines.
If you are using a combination of medicines, make sure that you
take each one at the proper time and do not mix them. Ask your
docor or pharmacist to help you plan a way to remember to take
your medicines at the right times.

While you are using methotrexate, your doctor may want you to
drink extra fluids so that you will pass more urine. This will help
the drug to pass from the body, and will prevent kidney problems
and keep your kidneys working well.

Methotrexate Injection USP commonly causes nausea and
vomiting. Even if you begin to feel ill, do not stop using this
medicine without first checking with your doctor. Ask your doctor
for ways to lessen these effects.

If you vomit shortly after taking a dose of methotrexate, check
with your doctor. You will be told whether to take the dose again
or to wait until the next scheduled dose.

**Usual dose:**
The dose of Methotrexate Injection USP will be different for
different patients. The dose that is used may depend on a number
of things, including what the medicine is being used for, the
patient's size, whether the medicine is being given by mouth or by
injection, and whether or not other medicines are also being taken.
If you are taking or receiving Methotrexate Injection USP at
home, follow your doctor's orders or the directions on the label. If
you have any questions about the proper dose of Methotrexate
Injection USP, ask your doctor.

If you take too much Methotrexate Injection USP (overdose):

<table>
<thead>
<tr>
<th>In case of drug overdose, contact your doctor, hospital emergency department or regional Poison Control Centre immediately.</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Do this even if you have no signs of discomfort.</td>
</tr>
<tr>
<td>• Always take the labelled medicine bottle with you, even if it is empty.</td>
</tr>
</tbody>
</table>

If you forget to take Methotrexate Injection USP (missed dose):

- If it is almost time for your next dose, skip the dose you
  missed and take your next dose when you are meant to.
- Otherwise, take it as soon as you remember, then contact
  your doctor for advice on when to take the next dose.
- Do not try to make up for missed doses by taking more
  than one dose at a time.
- Contact your doctor or pharmacist if you have any doubts
  or concerns about missed doses.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Along with their needed effects, medicines like Methotrexate
Injection USP can sometimes cause unwanted effects. Also,
because of the way these medicines act on the body, there is a
chance that they might cause other unwanted effects that may not
occur until months or years after the medicine is used. These
delayed effects may include certain types of cancer, such as
leukemia. Discuss these possible effects with your doctor.

The most common side effects include:
- Upset stomach, stomach pain, vomiting, nausea, loss of
  appetite, dizziness, chills and fever, diarrhea or sores on
  lips or mouth.
A fall in the number of white blood cells. This may reduce your resistance to infection and increase your chances of cold sores, blood poisoning or swelling of blood vessels.

Less common side effects are:
- Headaches, hair loss, mood changes, confusion, ringing in the ears, sore eyes, skin rashes, increased sensitivity to sunlight or unexplained weight loss.
- A fall in the number of other blood cells. This may increase your chances of bruising, bleeding or tiredness.
- Damage to the lungs.
- Harm to the unborn baby.

Rarely and generally at higher doses for treatment of other diseases, methotrexate can cause other side effects including:
- Liver damage, kidney damage, pain or difficulty urinating, lower back or side pain, blood in urine or stools, dark urine
- Fits, blurred vision, short term blindness
- Drowsiness, weakness
- Hoarseness
- Bloody vomit, black tarry stools or pin-point red spots on the skin
- Reddening or whitening of the skin, acne, boils, itching yellow skin or eyes
- Impotence or loss of interest in sex, decreased fertility, abortion
- Diabetes, thinning of the bones, painful muscles and joints

More rarely, it can cause:
- Skin rash and other skin disorders.
- Cancer of lymph glands, sudden death.
- Severe allergic reactions.

### SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and seek immediate emergency medical attention</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td>Common</td>
<td>Diarrhea or mouth ulcers</td>
<td>√</td>
</tr>
<tr>
<td></td>
<td>Sore throat, fever, chills, or swelling of glands</td>
<td>√</td>
</tr>
<tr>
<td>Less common</td>
<td>Chest pain, cough, shortness of breath or fever</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unusual bleeding or bruising</td>
<td>√</td>
</tr>
<tr>
<td>Rare</td>
<td>Signs of severe allergic reaction:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Skin rash, itching, chest tightness,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>wheezing, dizziness, hives,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>faintness, rapid heartbeat,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>shortness of breath, and/or a</td>
<td></td>
</tr>
<tr>
<td></td>
<td>swollen face, lips or tongue</td>
<td>√</td>
</tr>
<tr>
<td></td>
<td>Pain or difficulty urinating,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>lower back or side pain, blood in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>urine or stools, dark urine</td>
<td>√</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking Methotrexate Injection USP, contact your doctor or pharmacist.

### HOW TO STORE IT

To store this medicine:
- Keep out of reach of children.
- Store it at room temperature and away from heat and direct light. Avoid freezing Methotrexate Injection USP.
- Multidose vials should be stored in the refrigerator (between 2°C and 8°C) or at room temperature (between 15°C and 25°C) after the vials are punctured for a maximum of four weeks (30 days). Protect from light.
- Do not keep outdated medicine or medicine no longer needed. Be sure that any discarded medicine is out of reach of children.
Reporting Side Effects
You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:
- Online at MedEffect;
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
  Health Canada, Postal Locator
  0701E
  Ottawa, ON
  K1A 0K9
Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION
This document plus the full product monograph, prepared for health professionals can be found by contacting the sponsor, Sandoz Canada Inc., at: 1-800-361-3062 or by written request at:
145, Jules-Léger
Boucherville QC
J4B 7K8
or by e-mail at: medinfo@sandoz.com

This leaflet was prepared by Sandoz Canada Inc.

Last revised: September 21, 2016